Logo image of ONC

BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis

NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD

288.18  -10.11 (-3.39%)

After market: 288.18 0 (0%)

Fundamental Rating

4

Taking everything into account, ONC scores 4 out of 10 in our fundamental rating. ONC was compared to 550 industry peers in the Biotechnology industry. Both the profitability and financial health of ONC have multiple concerns. ONC is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ONC had positive earnings in the past year.
ONC had a positive operating cash flow in the past year.
ONC had negative earnings in each of the past 5 years.
ONC had a negative operating cash flow in each of the past 5 years.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

ONC has a Return On Assets of -7.51%. This is amongst the best in the industry. ONC outperforms 85.82% of its industry peers.
ONC's Return On Equity of -12.56% is amongst the best of the industry. ONC outperforms 87.64% of its industry peers.
Industry RankSector Rank
ROA -7.51%
ROE -12.56%
ROIC N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 84.66%, ONC belongs to the top of the industry, outperforming 87.82% of the companies in the same industry.
ONC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
ONC has more shares outstanding than it did 5 years ago.
ONC has a worse debt/assets ratio than last year.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

ONC has an Altman-Z score of 6.78. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
ONC has a better Altman-Z score (6.78) than 82.00% of its industry peers.
ONC has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
ONC has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: ONC underperforms 71.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 6.78
ROIC/WACCN/A
WACC9.49%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

A Current Ratio of 1.95 indicates that ONC should not have too much problems paying its short term obligations.
ONC has a Current ratio of 1.95. This is in the lower half of the industry: ONC underperforms 76.91% of its industry peers.
A Quick Ratio of 1.71 indicates that ONC should not have too much problems paying its short term obligations.
ONC has a worse Quick ratio (1.71) than 78.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.71
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 239.04%, which is quite impressive.
ONC shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.19%.
ONC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
EPS 1Y (TTM)239.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.51%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.53%

3.2 Future

ONC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 119.21% yearly.
Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 18.72% on average per year.
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y119.21%
Revenue Next Year37.04%
Revenue Next 2Y28.84%
Revenue Next 3Y24.14%
Revenue Next 5Y18.72%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1K 2K

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 4.50, the valuation of ONC can be described as very cheap.
ONC's Price/Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 98.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. ONC is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 64.35, the valuation of ONC can be described as expensive.
ONC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 88.91% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.09, ONC is valued quite expensively.
Industry RankSector Rank
PE 4.5
Fwd PE 64.35
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 50.96% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y64.57%
EPS Next 3Y50.96%

More info and screens

0

5. Dividend

5.1 Amount

ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (8/8/2025, 8:00:02 PM)

After market: 288.18 0 (0%)

288.18

-10.11 (-3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners30.27%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change35.22%
Market Cap31.19B
Analysts81.43
Price Target318.63 (10.57%)
Short Float %20.87%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.48
Dividend Growth(5Y)N/A
DP-14.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2455.21%
Min EPS beat(2)1800.57%
Max EPS beat(2)3109.85%
EPS beat(4)2
Avg EPS beat(4)1020.4%
Min EPS beat(4)-805.99%
Max EPS beat(4)3109.85%
EPS beat(8)3
Avg EPS beat(8)387.01%
EPS beat(12)4
Avg EPS beat(12)243.05%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.12%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)5.5%
Revenue beat(4)3
Avg Revenue beat(4)8.13%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)28.03%
Revenue beat(8)7
Avg Revenue beat(8)15.91%
Revenue beat(12)11
Avg Revenue beat(12)13.72%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.03%
PT rev (3m)23.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-70.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.07%
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)-0.41%
Valuation
Industry RankSector Rank
PE 4.5
Fwd PE 64.35
P/S 7.49
P/FCF N/A
P/OCF 237.39
P/B 8.89
P/tB 9.31
EV/EBITDA N/A
EPS(TTM)64.01
EY22.21%
EPS(NY)4.48
Fwd EY1.55%
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)1.21
OCFY0.42%
SpS38.46
BVpS32.42
TBVpS30.95
PEG (NY)0.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.51%
ROE -12.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.66%
FCFM N/A
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.71
Altman-Z 6.78
F-Score6
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)239.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.51%
EPS Next Y109.55%
EPS Next 2Y64.57%
EPS Next 3Y50.96%
EPS Next 5Y119.21%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.53%
Revenue Next Year37.04%
Revenue Next 2Y28.84%
Revenue Next 3Y24.14%
Revenue Next 5Y18.72%
EBIT growth 1Y72.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.94%
EBIT Next 3Y63.92%
EBIT Next 5Y54.61%
FCF growth 1Y86.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.02%
OCF growth 3YN/A
OCF growth 5YN/A